Adjunctive Donepezil in Attention Deficit Hyperactivity Disorder Youth: Case Series
- 1 September 2000
- journal article
- research article
- Published by Mary Ann Liebert Inc in Journal of Child and Adolescent Psychopharmacology
- Vol. 10 (3) , 217-222
- https://doi.org/10.1089/10445460050167322
Abstract
Despite well-documented improvement in attention deficit hyperactivity disorder (ADHD) in youths with the available single and combined pharmacologic agents, a number of youths remain with residual symptomatology causing impairment in multiple domains. Recent work has suggested a potential cognitive-enhancing role of cholinergic agents in ADHD. We describe five cases of ADHD youths aged 8-17 years being treated for ADHD with the acetylcholinesterase inhibitor donepezil (Aricept®), all of whom demonstrated improvement.Keywords
This publication has 5 references indexed in Scilit:
- Controlled Trial of High Doses of Pemoline for Adults With Attention-Deficit/Hyperactivity DisorderJournal of Clinical Psychopharmacology, 1999
- Diagnosis and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and AdolescentsJAMA, 1998
- Open-Label Treatment of Comorbid Depression and Attentional Disorders with Co-administration of Serotonin Reuptake Inhibitors and Psychostimulants in Children, Adolescents, and Adults: A Case SeriesJournal of Child and Adolescent Psychopharmacology, 1996
- Effects of acute subcutaneous nicotine on attention, information processing and short-term memory in alzheimer's diseasePsychopharmacology, 1992
- Release of dopamine and 5-hydroxytryptamine from rat striatal slices following activation of nicotinic cholinergic receptorsGeneral Pharmacology: The Vascular System, 1983